Home

JULIA MARIE EASTLAND

CIK 1500189 · CEO & President · last filed 2026-05-18

JULIA MARIE EASTLAND is a CEO & President who has filed 40 SEC Form 4 insider transactions across 8 companies since 2010. The most recent filing, for LNTH, was dated May 18, 2026. Across all open-market trades the lifetime net is +$28.1K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions. 4 SEC filings were submitted jointly with Lantheus Holdings, Inc.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.09M

Companies

8

Total Filings

40

Lifetime Open-Market Net

$28.1K

Filer Profile

Reported Address
C/O ZENTALIS PHARMACEUTICALS
10275 SCIENCE CENTER DRIVE, SUITE 200
SAN DIEGO, CA 92121
Related Filers
Lantheus Holdings, Inc. — 4 joint filings, latest 2026-05-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
LNTH Director 8,019 $100.25 $803.9K $0 3 2026-05-18
ZNTL CEO & President 80,022 $3.51 $280.9K $28.1K 5 2026-02-10
DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Director 16,071 $15.50 $249.1K $0 5 2024-05-28
Harpoon Therapeutics, Inc. (HARP) Delisted President and CEO 269,381 $23.01 $6.20M $0 10 2024-03-11
CALC Director 286 $1.98 $566 $0 1 2023-03-27
CalciMedica, Inc. (GRAY) Delisted Director — $5.50 — $0 3 2022-06-03
Cascadian Therapeutics, Inc. (CASC) Delisted CFO & CBO 5,237 — — $0 4 2018-02-02
Cascadian Therapeutics, Inc. (ONTY) Delisted CFO & VP Corp. Dev. 20,016 — — $0 8 2016-05-19

Recent Filings

40 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-18 LNTH Grant (A) +4,137 $0 EDGAR
2026-02-10 ZNTL Sell (S) −8,755 -$21.2K EDGAR
2026-01-09 ZNTL Grant (A) — $0 EDGAR
2025-05-16 LNTH Grant (A) +2,537 $0 EDGAR
2025-02-05 ZNTL Grant (A) +59,388 $0 EDGAR
2025-02-04 ZNTL Buy (P) +28,500 $49.3K EDGAR
2024-12-03 ZNTL Grant (A) — $0 EDGAR
2024-09-12 LNTH Grant (A) +1,345 $0 EDGAR
2024-05-28 DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted Grant (A) +5,357 $0 EDGAR
2024-03-11 Harpoon Therapeutics, Inc. (HARP) Delisted Mixed −238,131 $0 EDGAR
Showing 1–10 of 40
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.